The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity

Orumaa, Madleen; Kjær, Susanne K.; Dehlendorff, Christian; Munk, Christian; Olsen, Anne O.; Hansen, Bo T.; Campbell, Suzanne Hetzel; Nygård, Mari

doi:10.1016/j.vaccine.2019.12.016

Cited by 32 publications

(22 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To assess HPV prevalence in a hypothetical setting we assumed that vaccinetargeted HPV-types were eradicated, a highly likely situation. [22][23][24]37 The combined carcinogenic HPV types then excluded carcinogenic HPVs targeted by 2 v or 4 v (i.e., specimens positive to 31,33,35,39,45,51,52,56,58,59 and/or 68); and 9 v vaccines (i.e., specimens positive to 35,39,51,56,59 and/or 68). HPV genotype-specific prevalence for single infections, i.e., specimens positive only to one particular HPV genotype is also provided.…”

Section: Discussionmentioning

confidence: 99%

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Nygård

Hansen

Kjær

et al. 2020

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856).

show abstract

Section: Discussionmentioning

confidence: 99%

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Nygård

Hansen

Kjær

et al. 2020

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both the quadrivalent vaccine and its successor, the nona‐valent vaccine, cover HPV6 and HPV11. In countries with high HPV vaccination rates (>70–80%) such as Australia or Denmark, a significant decline of AGW has been observed shortly after the introduction of HPV vaccination 35,36 . Even in countries with moderate vaccination rates, some decrease in AGW has been observed 36 .…”

Section: Discussionmentioning

confidence: 99%

“…In countries with high HPV vaccination rates (>70-80%) such as Australia or Denmark, a significant decline of AGW has been observed shortly after the introduction of HPV vaccination. 35,36 Even in countries with moderate vaccination rates, some decrease in AGW has been observed. 36 This development will most likely influence the HPV-type spectrum found in AGW of children in the future.…”

Section: Discussionmentioning

confidence: 99%

“…35,36 Even in countries with moderate vaccination rates, some decrease in AGW has been observed. 36 This development will most likely influence the HPV-type spectrum found in AGW of children in the future. In our study, 52.8% of the analysed AGW was associated with HPV6 or HPV11, 84% in children 1-4 years of age and 25% in children above the age of four.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Human Papillomavirus‐type distribution in anogenital lesions of prepubertal children

Braun

Silling

Schloer

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background In contrast to adults, only limited data are available on the human papillomavirus (HPV)-type spectrum in anogenital warts (AGW) of children.Objective This study aimed to evaluate the HPV-type spectrum in AGW of prepubertal children. Materials & methodsIn a retrospective German multicentre study, HPV genotyping was performed in AGW biopsies of 55 1-to 12-year-old children using HPV group-specific PCRs followed by hybridization with type-specific probes or sequence analysis.Results Human papillomavirus-DNA was found in 53 of the 55 AGW. In 58.5% (31/53) of the HPV-positive AGW, mucosal HPV types were detected. HPV6 (27/53, 50.9%) was the predominant type. 43.4% (23/53) of the lesions were induced by cutaneous HPV types (HPV2, HPV27, HPV57). Mucosal HPV types were significantly more common in children under 5 years of age than in children 5 years of age and older (22/25, 88.0% [95% CI: 70.0-95.8] vs. 9/28, 32.1% [95% CI: 17.9-50.7], P < 0.001). In contrast, cutaneous HPV types were significantly more prevalent in the 5-to 12-year age group (4/25,.1], P < 0.001). ConclusionAnogenital warts in 5-to 12-year-old children are frequently associated with cutaneous HPV types, possibly due to horizontal transmission. HPV typing, in addition to comprehensive clinical and psychosocial evaluation, can potentially help in the assessment of these cases.

show abstract

“…Die HPV-Typen 6 und 11 sind als Niedrigrisiko eingestuft und verursachen genitale Warzen [4,19]. Aktuell werden 12 HPV-Typen (HPV 16,18,31,33,35,39,45,51,52,56,58,59) als Hochrisiko für die Entste-hung eines Zervixkarzinoms eingestuft [4,19]. Einige Hochrisiko-HPV-Typen, besonders HPV-Typ 16, sind mit hochgradigen intraepithelialen Neoplasien im Anogenitaltrakt assoziiert, die zu malignen Tumoren führen können [7,19].…”

Section: Hpv-assoziierte Krankheitenunclassified

HPV-Impfung zur Prävention von Genitalwarzen und Krebsvorstufen – Evidenzlage und Bewertung

Osmani

Klug

2021

Bundesgesundheitsbl

View full text Add to dashboard Cite

ZusammenfassungHumane Papillomviren (HPV) verursachen benigne und maligne Tumorerkrankungen. Bisher wurden mehr als 200 HPV-Typen entdeckt, von denen aktuell 12 als Hochrisiko für das Zervixkarzinom klassifiziert werden. HPV-Typen, die den Anogenitaltrakt befallen, werden sexuell übertragen. Seit 2006 sind prophylaktische HPV-Impfstoffe erhältlich. Die Impfung soll vor dem ersten sexuellen Kontakt erfolgen.HPV infizieren Epithelzellen und sind die häufigsten sexuell übertragenen Viren weltweit. Neben dem Zervixkarzinom verursachen HPV auch andere anogenitale Tumore, wie Vulva‑, Vagina- und Analkarzinom, aber auch Oropharynxkarzinome. Vor allem die Hochrisiko-HPV-Typen 16 und 18 werden hier gefunden. Des Weiteren sind die HPV-Typen 6 und 11 ursächlich für die Entstehung von genitalen Warzen. Aber auch harmlose Hautwarzen werden von HPV verursacht.HPV-Impfstoffe sind sicher und hochwirksam, wenn vor der Impfung noch keine HPV-Infektion vorliegt. Systematische Reviews und Metaanalysen haben gezeigt, dass die HPV-Impfung eine HPV-Infektion, aber auch präkanzeröse Läsionen im Anogenitaltrakt und Genitalwarzen wirksam verhindert. Mittlerweile liegen erste direkte Hinweise vor, dass die HPV-Impfung die Inzidenz des Zervixkarzinoms reduziert.Die Impfquoten variieren weltweit je nach Impfprogramm und Akzeptanz des HPV-Impfstoffs in der Bevölkerung. Deutschland hat im Vergleich zu anderen europäischen Ländern niedrige Impfquoten. Die Ständige Impfkommission (STIKO) empfiehlt die HPV-Impfung in Deutschland für alle Mädchen und Jungen im Alter von 9 bis 14 Jahren. Im Jahr 2018 waren nur die Hälfte aller 18-jährigen Mädchen in Deutschland vollständig gegen HPV geimpft.Organisierte Impfprogramme, bevölkerungsbezogen oder schulbasiert, sind notwendig, um hohe Impfquoten zu erreichen.

show abstract

The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity

Cited by 32 publications

References 48 publications

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Human Papillomavirus‐type distribution in anogenital lesions of prepubertal children

HPV-Impfung zur Prävention von Genitalwarzen und Krebsvorstufen – Evidenzlage und Bewertung

Contact Info

Product

Resources

About